{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:45:24Z","timestamp":1785386724953,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0505028"],"award-info":[{"award-number":["G0505028"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic HCV (CHC) infection is associated with autoimmunity. IgG autoantibodies to apolipoprotein A-I (AAA-I) predict all-cause mortality. We evaluated AAA-I in CHC patients and in those who were not viraemic, either because of spontaneous resolution (SR) of infection or HCV clearance following sustained virological response (SVR) after interferon therapy. We limited the study to HCV genotypes 1 and 3, the dominant HCV genotypes circulating in the UK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum samples from 126 CHC patients and 114 nonviraemic individuals (25 SR and 89 SVR) were assayed for AAA-I and lipoproteins. AUC was calculated for AAA-I and HDL-related parameters and used to predict cirrhosis. Fibronectin (FN) and FN-mRNA were measured in human hepatic stellate cells (LX-2) in the presence or absence of AAA-I.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AAA-I was found in 47% of patients with CHC, 37% of SVR patients, and 16% of SR individuals (CHC vs. SR, <jats:italic>p<\/jats:italic> = 0.004). AAA-I levels in CHC patients were higher in those with cirrhosis (<jats:italic>p<\/jats:italic> = 0.0003). The AUC for AAA-I, apoA-I, and HDL-C in predicting cirrhosis was 0.72 (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), 0.65 (<jats:italic>p<\/jats:italic> = 0.01), and 0.64 (<jats:italic>p<\/jats:italic> = 0.02). After 48 h in the presence of AAA-I, LX-2 cells showed an 80% increase in FN-mRNA compared to the LX-2\/IgG control (<jats:italic>p<\/jats:italic> = 0.028) and higher levels of FN (<jats:italic>p<\/jats:italic> = 0.0016).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CHC is often associated with AAA-I, and these can persist after SVR. AAA-I is a robust predictor of cirrhosis in CHC infection. LX-2 cells exposed to AAA-I showed increased FN. Further studies are warranted to define the role of AAA-I in promoting not only viral persistence but also fibrosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1461041","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T05:23:55Z","timestamp":1742448235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Autoantibodies to apolipoprotein A-I in hepatitis C virus infection: a role in disease progression?"],"prefix":"10.3389","volume":"16","author":[{"given":"Simon H.","family":"Bridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac T.","family":"Shawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Marin-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Cramp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Taylor-Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vuilleumier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Dermot G.","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret F.","family":"Bassendine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41584-023-00964-y","article-title":"High risk of autoimmune diseases after COVID-19","volume":"19","author":"Sharma","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0168-8278(99)80372-9","article-title":"Autoimmunity and extrahepatic manifestations in hepatitis C virus infection","author":"Manns","year":"1999","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","article-title":"Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies","volume":"248","author":"Bartenschlager","year":"2018","journal-title":"Virus Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cld.978","article-title":"Hepatitis C virus elimination by 2030: conquering mount improbable","volume":"16","author":"Dhiman","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074001","article-title":"Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study","volume":"382","author":"Hamill","year":"2023","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00437","article-title":"Anti-apolipoprotein A-1 IgG predict all-cause mortality and are associated with Fc receptor-like 3 polymorphisms","volume":"8","author":"Antiochos","year":"2017","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12072-018-9842-5","article-title":"Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis","volume":"12","author":"Bridge","year":"2018","journal-title":"Hepatol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e13818","DOI":"10.1111\/eci.13818","article-title":"Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence","volume":"52","author":"L\u2019Huillier","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jim.2019.03.011","article-title":"ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1","volume":"469","author":"Frias","year":"2019","journal-title":"J Immunol Methods"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0004563215594818","article-title":"Biochemistry laboratories should routinely report non-HDL-cholesterol","volume":"52","author":"Preiss","year":"2015","journal-title":"Ann Clin Biochem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132780","article-title":"The human autoantibody response to apolipoprotein A-I is focused on the C-terminal helix: A new rationale for diagnosis and treatment of cardiovascular disease","volume":"10","author":"Pagano","year":"2015","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq055","article-title":"Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction","volume":"31","author":"Vuilleumier","year":"2010","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.849166","article-title":"Cardiovascular risk prediction: basic concepts, current status, and future directions","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-03-0248","article-title":"Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study","volume":"116","author":"Antiochos","year":"2016","journal-title":"Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.05.035","article-title":"Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study)","volume":"53","author":"Degos","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ajhg.2022.01.001","article-title":"Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQbeta1","volume":"109","author":"Valencia","year":"2022","journal-title":"Am J Hum Genet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cells8030233","article-title":"HCV Pit Stop at the Lipid Droplet: Refuel Lipids and\u00a0Put on a Lipoprotein Coat before Exit","volume":"8","author":"Vieyres","year":"2019","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307527110","article-title":"Ultrastructural analysis of hepatitis C virus particles","volume":"110","author":"Catanese","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hep.25628","article-title":"High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients","volume":"56","author":"Scholtes","year":"2012","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.11.023","article-title":"Comparative proteomic profiling of plasma very-low-density and low-density lipoproteins","volume":"411","author":"Sun","year":"2010","journal-title":"Clin Chim Acta"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.211292","article-title":"Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins","volume":"60","author":"Mancone","year":"2011","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004534","article-title":"Amphipathic alpha-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles","volume":"10","author":"Fukuhara","year":"2014","journal-title":"PloS Pathog"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/v15030782","article-title":"The role of viral infections\u00a0in\u00a0the onset of autoimmune diseases","volume":"15","author":"Sundaresan","year":"2023","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1991.tb00601.x","article-title":"T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease","volume":"122","author":"Zinkernagel","year":"1991","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/329547a0","article-title":"Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site","volume":"329","author":"Milich","year":"1987","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00194-12","article-title":"Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells","volume":"19","author":"Roughan","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.12.010","article-title":"Immune responses to HCV and other hepatitis viruses","volume":"40","author":"Park","year":"2014","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.019","article-title":"Increased peripheral CD4(+) regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C","volume":"66","author":"Langhans","year":"2017","journal-title":"J Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"Imbert-Bismut","year":"2001","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.026","article-title":"HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure","volume":"73","author":"Trieb","year":"2020","journal-title":"J Hepatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cells9010024","article-title":"Metabolic hallmarks of hepatic stellate cells in liver fibrosis","volume":"9","author":"Khomich","year":"2019","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.173575","article-title":"Antiinflammatory actions of HDL: a new insight","volume":"28","author":"Rye","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-12-1039","article-title":"Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4","volume":"114","author":"Montecucco","year":"2015","journal-title":"Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2012.02530.x","article-title":"Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2\/CD14 complex","volume":"272","author":"Pagano","year":"2012","journal-title":"J Intern Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22484","article-title":"Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection","volume":"48","author":"Hoare","year":"2008","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22728","article-title":"Is there disease progression in patients who are hepatitis C virus antibody-positive and hepatitis C virus RNA-seronegative","volume":"48","author":"Wiesner","year":"2008","journal-title":"Hepatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/vaccines8030380","article-title":"Regulatory B cells and their cytokine profile in HCV-related hepatocellular carcinoma: association with regulatory T cells and disease progression","volume":"8","author":"Hetta","year":"2020","journal-title":"Vaccines (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1461041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T05:23:59Z","timestamp":1742448239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1461041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1461041"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1461041","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"article-number":"1461041"}}